Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Michaelides

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Investigation|November 16, 2013
Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depressionSarah Ann R Anderson, Michael Michaelides, Parisa Zarnegar, et al.
Scientific Reports|January 22, 2024
Synthesis and preclinical evaluation of [<sup>11</sup>C]uPSEM792 for PSAM<sup>4</sup>-GlyR based chemogeneticsSridhar Goud Nerella, Sanjay Telu, Jeih-San Liow, et al.
Molecular Imaging and Biology|August 23, 2022
6-O-(2-[<sup>18</sup>F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([<sup>18</sup>F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In VivoMarjorie R Levinstein, Emilya N Ventriglia, Juan L Gomez, et al.
Biological Psychiatry|February 25, 2023
Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse LiabilityMarjorie R Levinstein, Meghan L Carlton, Tommaso Di Ianni, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
D2 autoreceptors gate vulnerability to cocaine use disorderErin M Murray, Daniel Diaz-Urbina, Roland Bock, et al.
Neuroendocrinology|November 6, 2008
Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesityLisa M Davis, Michael Michaelides, Lawrence J Cheskin, et al.
The European Journal of Neuroscience|May 8, 2019
Ultrastructural localization of DREADDs in monkeysAdriana Galvan, Jessica Raper, Xing Hu, et al.
Journal of Medicinal Chemistry|December 13, 2002
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailabilityPhilip J Hajduk, Suzanne B Shuker, David G Nettesheim, et al.
Molecular Psychiatry|April 16, 2021
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liabilityJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Science (New York, N.Y.)|August 5, 2017
Chemogenetics revealed: DREADD occupancy and activation via converted clozapineJuan L Gomez, Jordi Bonaventura, Wojciech Lesniak, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Investigation|November 16, 2013
Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depressionSarah Ann R Anderson, Michael Michaelides, Parisa Zarnegar, et al.
Scientific Reports|January 22, 2024
Synthesis and preclinical evaluation of [<sup>11</sup>C]uPSEM792 for PSAM<sup>4</sup>-GlyR based chemogeneticsSridhar Goud Nerella, Sanjay Telu, Jeih-San Liow, et al.
Molecular Imaging and Biology|August 23, 2022
6-O-(2-[<sup>18</sup>F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([<sup>18</sup>F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In VivoMarjorie R Levinstein, Emilya N Ventriglia, Juan L Gomez, et al.
Biological Psychiatry|February 25, 2023
Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse LiabilityMarjorie R Levinstein, Meghan L Carlton, Tommaso Di Ianni, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
D2 autoreceptors gate vulnerability to cocaine use disorderErin M Murray, Daniel Diaz-Urbina, Roland Bock, et al.
Neuroendocrinology|November 6, 2008
Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesityLisa M Davis, Michael Michaelides, Lawrence J Cheskin, et al.
The European Journal of Neuroscience|May 8, 2019
Ultrastructural localization of DREADDs in monkeysAdriana Galvan, Jessica Raper, Xing Hu, et al.
Journal of Medicinal Chemistry|December 13, 2002
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailabilityPhilip J Hajduk, Suzanne B Shuker, David G Nettesheim, et al.
Molecular Psychiatry|April 16, 2021
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liabilityJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Science (New York, N.Y.)|August 5, 2017
Chemogenetics revealed: DREADD occupancy and activation via converted clozapineJuan L Gomez, Jordi Bonaventura, Wojciech Lesniak, et al.
Pageof 12